DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.

ABSTRACT:

Background

Levodopa-carbidopa intestinal gel (LCIG) is an established treatment for improving motor and some non-motor symptoms (NMS) in patients with advanced Parkinson's disease (PD). Prospective long-term data in routine clinical practice are limited.

Objective

Assess LCIG effectiveness and safety in patients with advanced PD after 12 months during real-world routine clinical practice.

Methods

Duodopa/Duopa in patients with advanced Parkinson's disease-a global observational study evaluating long-term effectiveness (DUOGLOBE) (NCT02611713) is an ongoing, prospective, multinational, observational study of LCIG-naïve patients treated as part of routine clinical practice; 3 years of follow-up are planned. The primary outcome is the change in patient-reported off

SUBMITTER: Standaert DG 

PROVIDER: S-EPMC8485588 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature